Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9179610
Knihovny.cz E-resources
- MeSH
- Adenine analogs & derivatives pharmacology MeSH
- Antiviral Agents pharmacology MeSH
- Cell Division drug effects MeSH
- Injections, Intraperitoneal MeSH
- Rats MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Lymphoma, T-Cell drug therapy MeSH
- Mice MeSH
- Lung cytology MeSH
- CD4-CD8 Ratio drug effects MeSH
- Rats, Sprague-Dawley MeSH
- Antineoplastic Agents pharmacology MeSH
- Spleen cytology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine MeSH Browser
- Adenine MeSH
- Antiviral Agents MeSH
- bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine MeSH Browser
- Antineoplastic Agents MeSH
PMEDAP and/or PMEA treatment of SD rat lymphomas significantly prolonged the mean survival time of tumor-bearing animals. Dose-dependent genotoxicity of both PMEDAP and PMEA was not observed in in vitro tests on stabilized diploid MRC-5 cell line. The mitotic activity of MRC-5 cells was completely inhibited after 48 hours exposure in culture medium containing PMEDAP (10 micrograms/ml), or PMEA (25 micrograms/ml), respectively. Significant concentration dependent inhibition of cell proliferation caused by PMEDAP and/or PMEA was also observed in murine splenocytes. The analogs specifically inhibit proliferation of mitogen-activated T-lymphocytes. Modulation of subpopulations of peripheral blood cells under in vivo conditions was found in inbred SD animals. Intraperitoneal administration of PMEDAP to young healthy SD animals induced the decrease of the CD4+/CD8+ value from 1.3-1.6 to 0.72 while i.p. application of PMEA caused a decrease of the same ratio to 0.62.
